Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 221

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 221
---
:

•

you may send another proxy card with a later date;

•

you may notify Sumit Mehta, Iris’s Chief Executive Officer, in writing before the Special Meeting that you have revoked your proxy; or

•

you may attend the Special Meeting, revoke your proxy, and vote in person (which would include presence at the virtual Special Meeting), as indicated above.

No Additional Matters May Be Presented at the Special Meeting

The Special Meeting has been called only to consider the approval of the Business Combination Proposal, the Nasdaq Proposal, the Incentive Plan Proposal the ParentCo Charter Proposal, the Advisory Charter Proposals, the Election of Directors Proposal and the Adjournment Proposal. Under our bylaws, other than procedural matters incident to the conduct of the Special Meeting, no other matters may be considered at the Special Meeting if they are not included in this proxy statement/prospectus.

#### Who Can Answer Your Questions About Voting
If you are a stockholder and have any questions about how to vote or direct a vote in respect of your shares of Iris common stock, please contact Alliance Advisors, LLC, our proxy solicitor, toll-free at (844)-670-2141 or email at IRAA@allianceadvisors.com.

### Redemption Rights and Procedures
Pursuant to our charter, in connection with the Business Combination, public stockholders may request that Iris redeem all or a portion of such public stockholder’s shares of Iris Class A Common Stock

<div align='center'>100</div>

TABLE OF CONTENTS

for a pro rata portion of cash from the Trust Account if demand is properly made and the Business Combination is consummated. These shares, immediately prior to the Business Combination, will cease to be outstanding and will represent only the right to receive a pro rata share of the aggregate amount on deposit in the Trust Account (calculated as of two business days prior to the consummation of the Business Combination, less franchise and income taxes payable). For illustrative purposes, based on funds in our Trust Account of approximately $2,001,033 (as adjusted for redemptions paid out of the Trust Account in January 2025) as of January 2, 2025, stockholders would have received a redemption price of approximately $11.47 per share (net of all applicable taxes payable from the Trust Account) of Iris Class A Common Stock

In order to exercise your redemption rights, you must:

•

submit a request in writing that we redeem your public shares for cash. The request